RxDoctor Payments Data

Ali Sanai, MD

Internal Medicine · Baltimore, MDNPI 1689728545

Payments from drug & device makers

$467in general payments, 2019–2025

Across 12 payments — averaging $38.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$142
  • Pfizer$132
  • Boston Scientific$93
  • GSK$22
  • Amarin Pharma, Inc.$21
  • Biohaven Pharmaceuticals, Inc.$16
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$36979%
  • Education$9921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$467 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$36,833
Medicare patients
60
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$26,559
Spiriva HandihalerTiotropium Bromide11$5,933
SymbicortBudesonide/Formoterol Fumarate11$3,376
Atorvastatin Calcium49$935
Levothyroxine Sodium37$705
Rosuvastatin Calcium36$659
Valsartan12$573
Metoprolol Succinate26$470
Memantine Hcl16$468
Famotidine14$339
Tamsulosin Hcl17$290
Donepezil Hcl12$236
Divalproex Sodium15$234
Losartan Potassium15$197
Furosemide25$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$26,55922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →